Paper Details

  1. Home
  2. Paper Details

Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA.

Author: ChenJing Voon, GahnJames C, MuddPaul N, NesheimJeffrey

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This analysis assessed the budget impact of introducing the β<sub>3</sub>-adrenergic agonist vibegron for the treatment of overactive bladder (OAB) in the US from commercial payor and Medicare perspectives.
Paper Details　
Original Abstract of the Article :
Label="BACKGROUND">Overactive bladder (OAB) is associated with considerable clinical and economic burden. Treatment of patients with OAB using anticholinergics is limited by tolerability issues and increased anticholinergic burden, which is associated with increased risk of dementia and falls/fractu...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522665/

データ提供：米国国立医学図書館（NLM）

Vibegron: A Potential Oasis in the Desert of Overactive Bladder

Overactive bladder (OAB) is a common and bothersome condition that can significantly impact quality of life. This study examines the potential cost-effectiveness of introducing vibegron, a new medication for OAB, into the US healthcare system. The researchers conducted a budget impact analysis to assess the economic implications of using vibegron compared to existing treatments, considering both commercial payor and Medicare perspectives.

Vibegron: A Cost-Effective Oasis

The study found that introducing vibegron could potentially lead to cost savings in the long term, particularly for patients with OAB who experience tolerability issues with anticholinergics. This suggests that vibegron could be a more cost-effective option for some patients with OAB, potentially reducing the overall healthcare burden associated with this condition. Imagine a desert traveler encountering two oases – one offering abundant water and resources, while the other is more limited. Vibegron could be like the more abundant oasis, offering not only relief but also potential cost-savings for those seeking treatment for OAB.

Navigating the Desert of OAB

The authors acknowledge that further research is needed to fully understand the long-term cost-effectiveness of vibegron. However, this study provides a preliminary indication that vibegron could be a valuable addition to the treatment options for OAB, offering both clinical benefits and potential cost savings. As we continue to explore the desert of OAB research, we need to consider both clinical efficacy and economic implications to develop sustainable and cost-effective treatment strategies.

Dr.Camel's Conclusion

This study suggests that vibegron could be a potential oasis in the desert of OAB, offering both clinical benefits and potential cost savings. While further research is needed to confirm its long-term cost-effectiveness, it presents a promising new option for managing OAB and reducing the overall healthcare burden associated with this condition.

Date :
  1. Date Completed 2022-10-03
  2. Date Revised 2022-11-01
Further Info :

Pubmed ID

35881325

DOI: Digital Object Identifier

PMC9522665

Related Literature

Article Analysis
・Side Effects of vibegron
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.